Uniqure nv QURE.US 總覽分析
QURE 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
QURE 近期報酬表現
7.58%
Uniqure nv
1.99%
同產業平均
-0.64%
S&P500
與 QURE 同產業的標的表現
- MGX Metagenomi inc價值 -趨勢 3 分波段 2 分籌碼 1 分股利 1 分查看更多
QURE 公司資訊
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company's lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington's disease is in Phase I/II clinical study.